This study evaluates PF-07260437, a B7-H4xCD3 bispecific antibody, which redirects T cells to kill B7-H4+ breast cancer cells. Significant tumor regression was observed in humanized preclinical models, particularly when combined with anti-PD-1, palbociclib, or fulvestrant. The bispecific increased CD8+ T cell infiltration and enhanced immune-mediated tumor killing.
PF-07260437 shows strong anti-tumor efficacy, especially in combination with standard therapies, and promotes T cell infiltration and immune activation in B7-H4+ tumors.
Humanized CD3ε Knockin mouse model generated by genOway, used to assess PF-07260437 in an immunocompetent T cell context; combined with B7-H4+ tumor models.
Breast cancer, Immunotherapy, CD3 bispecifics, T cell redirection, Combination therapy
Humanized Knockin, CD3ε, Bispecific antibody, T cell engager
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
